(Q38161794)

30 August 2017

Emerging cell and cytokine targets in rheumatoid arthritis (English)

1 reference

30 August 2017

1 reference

Gerd-Rüdiger Burmester

series ordinal

1

object named as

Gerd R Burmester

1 reference

30 August 2017

Eugen Feist

2

1 reference

30 August 2017

Thomas Dörner

series ordinal

3

1 reference

30 August 2017

language of work or name

English

0 references

publication date

12 November 2013

1 reference

Nature Reviews Rheumatology

30 August 2017

1 reference

30 August 2017

10

1 reference

30 August 2017

2

1 reference

30 August 2017

77-88

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2013.168

30 August 2017

0 references

cites work

Autoimmune arthritis: the interface between the immune system and joints

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

The pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Inflammatory bone loss: pathogenesis and therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Secretion of gelatinases and activation of gelatinase A (MMP-2) by human rheumatoid synovial fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Rheumatoid arthritis progression mediated by activated synovial fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Cytokines in the pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

The pathogenesis of rheumatoid arthritis: new insights from old clinical data?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Ten years with biologics: to whom do data on effectiveness and safety apply?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

JAKs and STATs in immunity, immunodeficiency, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Small molecules targeting JAKs--a new approach in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Is there a feudal hierarchy amongst regulatory immune cells? More than just Tregs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

The role of regulatory T cells in antigen-induced arthritis: aggravation of arthritis after depletion and amelioration after transfer of CD4+CD25+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Induced T regulatory cells suppress osteoclastogenesis and bone erosion in collagen-induced arthritis better than natural T regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Plasticity of CD4(+) FoxP3(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Regulatory T cells as therapeutic targets in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

CD4+CD25high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Immunity to citrullinated proteins in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. Differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Therapeutic potential of Tregs to treat rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Interleukin-2 and regulatory T cells in graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Tregitope update: mechanism of action parallels IVIg

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

B-cell-directed therapies for autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Antibodies to citrullinated proteins in arthritis: pathology and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Mechanisms of killing by anti-CD20 monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Expression of cell surface markers after human B lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren’s syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

A multitude of kinases--which are the best targets in treating rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Regulatory B cells in autoimmunity: developments and controversies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Colony-stimulating factors in inflammation and autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

An overview of IL-17 function and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Interleukin-17 and type 17 helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Th17 and natural Treg cell population dynamics in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Increased apoptotic chondrocytes in articular cartilage from adult heterozygous SirT1 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Increased Interleukin 21 (IL-21) and IL-23 Are Associated with Increased Disease Activity and with Radiographic Status in Patients with Early Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Nuclear receptor NR4A2 orchestrates Th17 cell-mediated autoimmune inflammation via IL-21 signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

MicroRNAs in rheumatoid arthritis: potential role in diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

B-cell depletion in the treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Pulmonary Alveolar Proteinosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

A reexamination of the relationship between active rheumatoid arthritis and the acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

The tissue architecture of synovial membranes in inflammatory and non-inflammatory joint diseases. I. The localization of the major synovial cell populations as detected by monoclonal reagents directed towards Ia and monocyte-macrophage antigens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Pulmonary alveolar proteinosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

The gene expression of type 17 T-helper cell-related cytokines in the urinary sediment of patients with systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

IL-21 regulates Th17 cells in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.168

Evidence for GM-CSF receptor expression in synovial tissue. An analysis by semi-quantitative polymerase chain reaction on rheumatoid arthritis and osteoarthritis synovial biopsies

31 March 2020

1 reference

12 December 2020

Characterization of a human B lymphocyte-specific antigen.

1 reference

12 December 2020

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

1 reference

12 December 2020

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study

1 reference

12 December 2020

CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity

1 reference

12 December 2020

The central role of T cells in rheumatoid arthritis

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2013.168

1 reference

Dimensions Publication ID

30 August 2017

0 references

1 reference